Related Experiment Video
Updated: May 25, 2026
08:40
Spatial and Temporal Analysis of Active ERK in the C. elegans Germline
Published on: November 29, 2016
DARPP-32 is required for MAPK/ERK signaling in thyroid cells
Ana Chocarro-Calvo1, Miguel A Zaballos, Pilar Santisteban
1Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Avda de Atenas s/n Alcorcón, Madrid, Spain. custodia.garcia@urjc.es
Molecular Endocrinology (Baltimore, Md.)
|February 4, 2012
Summary
Dopamine and cAMP-regulated neuronal phosphoprotein (DARPP-32) controls MAPK/ERK signaling duration, influencing thyroid cell differentiation. Fine-tuning DARPP-32 levels impacts MAPK pathway kinetics and sensitivity, offering a potential therapeutic target for thyroid cancer.
Area of Science:
- Cellular signaling pathways
- Molecular endocrinology
- Cancer biology
Background:
- Mitogen-activated protein kinase (MAPK) signaling duration dictates cellular outcomes like proliferation or differentiation.
- Integrating MAPK kinetics with other cellular signals is crucial for development and cancer research.
- Dopamine and cAMP-regulated neuronal phosphoprotein, 32 kDa (DARPP-32) is essential for thyroid cell differentiation.
Purpose of the Study:
- To investigate the role of DARPP-32 in determining the duration of MAPK/ERK activation.
- To elucidate how DARPP-32 integrates with other signaling pathways, such as those initiated by serum, TSH, and IGF-I.
- To explore the therapeutic potential of DARPP-32 in thyroid cancer.
Main Methods:
- Stimulation of thyroid cells with serum, TSH, and IGF-I to activate MAPK signaling.
- Assessment of DARPP-32 levels and MAPK/ERK activation kinetics under different stimulation conditions.
- Utilizing small interfering RNA (siRNA) to block de novo DARPP-32 expression and evaluate its impact on MAPK/ERK signaling sensitivity.
Main Results:
- Serum stimulation leads to transient MAPK pathway activation, independent of DARPP-32 levels.
- TSH + IGF-I stimulation results in sustained MAPK activation due to increased DARPP-32 expression.
- Blocking DARPP-32 expression with siRNA abolishes the sensitivity of MAPK/ERK signaling in thyroid cells.
- DARPP-32's regulation by cAMP/protein kinase A influences protein phosphatase 1 activity, a key MAPK kinase regulator.
Conclusions:
- DARPP-32 acts as a critical determinant of MAPK/ERK signaling duration and sensitivity in thyroid cells.
- The cAMP/PKA pathway, through DARPP-32, modulates MAPK pathway kinetics, explaining TSH's control over MAPK activity duration.
- Loss of DARPP-32 in thyroid tumors suggests its potential as a therapeutic target for thyroid cancer.
Related Concept Videos
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:00Enzyme-linked Receptors
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:25cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...